Provided herein are improved methods for producing recombinant Adeno-Associated Virus (rAAV) particles. In some embodiments, a method for producing recombinant AAV (rAAV) particles provided herein comprises culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor. In some embodiments, a method for producing recombinant AAV (rAAV) particles provided herein comprises culturing cells capable of producing rAAV particles in the presence of a histone deacetylase (HDAC) inhibitor and increased amount of a sodium salt.

Cystic Fibrosis (CF) is a recessive, lethal genetic disease in which many patients have inherited DNA mutations that create a CFTR protein that is produced, but ineffective in its function. The present disclosure generally pertains to methods and products for increasing CFTR production through the use of a CRISPR/dCas9 system. This disclosure describes such system, which comprises gRNA configured to target the CFTR domain and dCas9 configured to upregulate expression of the gRNA target, and methods of using the same.

The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

Provided is a papillomavirus chimeric protein, the skeleton thereof being a papillomavirus L1 protein or a mutant thereof, at least one human papillomavirus 33-type L2 protein or mutant polypeptide thereof being embedded on the skeleton. The present papillomavirus chimeric protein can be used for preparing a vaccine for preventing papillomavirus infections and infection induced disease.

The invention provides methods for enhancing the delivery of viral vectors to the eye of a subject by administering a proteasome inhibitor or and a viral vector ending a gene of interest to the eye.

The invention provides methods for enhancing the delivery of viral vectors to the eye of a subject by administering a proteasome inhibitor or and a viral vector ending a gene of interest to the eye.

The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.

Provided are polypeptides that have at least about 95% but less than 100% sequence identity to SEQ ID NO: 2, optionally wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 4, with the proviso that the polypeptide does not have 100% sequence identity to SEQ ID NO: 2. Also provided are polypeptides that include an amino acid sequence that is a variant of SEQ ID NO: 2, wherein the variant sequence has at least one substitution at an amino acid position selected from the group consisting of D287, D291, D311, N313, D315, L307, and N284 of SEQ ID NO: 2; optionally wherein the polypeptide inhibits growth of a microbe and/or microbial biofilm and/or disrupts a microbial biofilm; nucleic acid molecules encoding the disclosed polypeptides; vectors and recombinant host cells that include the disclosed nucleic acid molecules; antimicrobial compositions that include an effective amount of the disclosed polypeptides, optionally that also include a carrier and/or one or more additional active agents; and methods for inhibiting the growth of microbes and/or microbial biofilms on surfaces and/or for disrupting microbial biofilms on surfaces and methods for inhibiting the growth of microbes on and/or in agricultural products and/or subjects.

Provided are polypeptides that have at least about 95% but less than 100% sequence identity to SEQ ID NO: 2, optionally wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 4, with the proviso that the polypeptide does not have 100% sequence identity to SEQ ID NO: 2. Also provided are polypeptides that include an amino acid sequence that is a variant of SEQ ID NO: 2, wherein the variant sequence has at least one substitution at an amino acid position selected from the group consisting of D287, D291, D311, N313, D315, L307, and N284 of SEQ ID NO: 2; optionally wherein the polypeptide inhibits growth of a microbe and/or microbial biofilm and/or disrupts a microbial biofilm; nucleic acid molecules encoding the disclosed polypeptides; vectors and recombinant host cells that include the disclosed nucleic acid molecules; antimicrobial compositions that include an effective amount of the disclosed polypeptides, optionally that also include a carrier and/or one or more additional active agents; and methods for inhibiting the growth of microbes and/or microbial biofilms on surfaces and/or for disrupting microbial biofilms on surfaces and methods for inhibiting the growth of microbes on and/or in agricultural products and/or subjects.